Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00824460 · ClinicalTrials.gov registry record · Phase 2
Study of Phosphate Levels in Patients With Chronic Kidney Disease
A Phase 2 study of Chronic Kidney Disease, sponsored by Vifor Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
- 20
- Study locations
NCT00824460: Completed Phase 2 study of Chronic Kidney Disease, sponsored by Vifor Pharma.
NCT00824460 is a Phase 2 study of Chronic Kidney Disease that has completed, run by Vifor Pharma. The registered enrollment target is 154 participants, below the 3,205-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00824460, a Phase 2 study of Chronic Kidney Disease, has completed, sponsored by Vifor Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.
Conditions Studied
Interventions
- DRUG 1.25 g PA21 (250 mg iron)
- DRUG 5.0 g PA21 (1,000 mg iron)
- DRUG 7.5 g PA21 (1,500 mg iron)
- DRUG 10.0 g PA21 (2,000 mg iron)
- DRUG 12.5 g PA21 (2,500 mg iron)
Study Locations (20)
Other
- MHAT - Gabrovo
- MHAT Plovdiv - Plovdiv
- Department of Haemodialysis at MHAT - Rousse
- 5th MHAT Sofia - Sofia
- SHATCVD - National Cardiology Hospital - Sofia
- MHAT "Tokuda Hospital Sofia" - Sofia
- UMHAT "Alexandrovska" Dialysis Clinic - Sofia
- UMHAT "Sveti Ivan Rilski" - Sofia
- UMHAT "Sveta Anna" - Sofia
- MDHAT Department of Haemodialysis and Nephrology - Veliko Tarnovo
- Opca bonica Bjelovar - Bjelovar
Colorado
- Western Nephrology & Metabolic Disease - Arvada
- Complete Renal Care - Denver
Tennessee
- Southeast Renal Research Institute - Chattanooga
- Nephrology Associates - Nashville
Florida
- Pines Clinical Research - Pembroke Pines
Kansas
- University of Kansas Medical Center - Kansas City
New York
- Nephrology Associates - Fresh Meadows
Ohio
- University Hospitals / Case Medical Center - Cleveland
Texas
- Southwest Houston Research - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
What the finished NCT00824460 record still lists
NCT00824460 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 3,205-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 5 interventions - of which 1.25 g PA21 (250 mg iron) is the first listed.
NCT00824460 names 20 study sites across 8 states, led by Other, Colorado, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00824460 about?
NCT00824460 is a clinical study titled "Study of Phosphate Levels in Patients With Chronic Kidney Disease". The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.
What is the current status of trial NCT00824460?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2008-12. Estimated completion is 2010-03.
What conditions does trial NCT00824460 study?
This clinical trial studies the following conditions: Chronic Kidney Disease.
What interventions are being tested in trial NCT00824460?
The interventions under investigation include: 1.25 g PA21 (250 mg iron) (DRUG), 5.0 g PA21 (1,000 mg iron) (DRUG), 7.5 g PA21 (1,500 mg iron) (DRUG), 10.0 g PA21 (2,000 mg iron) (DRUG), 12.5 g PA21 (2,500 mg iron) (DRUG).
Who is sponsoring clinical trial NCT00824460?
This trial is sponsored by Vifor Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00824460 being conducted?
This trial has 20 study locations across Colorado, Florida, Kansas, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00824460's enrollment target sits among peer trials
154 45th of 101 higher than 57 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
RECRUITING · Phase 2
-
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
RECRUITING · Phase 2
-
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
RECRUITING · Phase 2
-
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
ACTIVE NOT RECRUITING · Phase 2
-
Metformin in Kidney Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia